CA2180843A1 - Modulateurs a base de pyridine agissant sur les recepteurs de l'acetylcholine - Google Patents

Modulateurs a base de pyridine agissant sur les recepteurs de l'acetylcholine

Info

Publication number
CA2180843A1
CA2180843A1 CA002180843A CA2180843A CA2180843A1 CA 2180843 A1 CA2180843 A1 CA 2180843A1 CA 002180843 A CA002180843 A CA 002180843A CA 2180843 A CA2180843 A CA 2180843A CA 2180843 A1 CA2180843 A1 CA 2180843A1
Authority
CA
Canada
Prior art keywords
disorders
disease
compounds
modulators
acetylcholine receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002180843A
Other languages
English (en)
Other versions
CA2180843C (fr
Inventor
Ian A. Mcdonald
Jeffrey P. Whitten
Nicholas D. Cosford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/337,640 external-priority patent/US5594011A/en
Application filed by Individual filed Critical Individual
Publication of CA2180843A1 publication Critical patent/CA2180843A1/fr
Application granted granted Critical
Publication of CA2180843C publication Critical patent/CA2180843C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002180843A 1994-11-10 1995-10-16 Modulateurs a base de pyridine agissant sur les recepteurs de l'acetylcholine Expired - Fee Related CA2180843C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/337,640 US5594011A (en) 1994-11-10 1994-11-10 Modulators of acetylcholine receptors
US08/337,640 1995-06-07
US08/485,398 1995-06-07
US08/485,398 US5703100A (en) 1994-11-10 1995-06-07 Modulators of acetylcholine receptors
PCT/US1995/013068 WO1996015123A1 (fr) 1994-11-10 1995-10-16 Modulateurs a base de pyridine agissant sur les recepteurs de l'acetylcholine

Publications (2)

Publication Number Publication Date
CA2180843A1 true CA2180843A1 (fr) 1996-05-23
CA2180843C CA2180843C (fr) 2003-07-15

Family

ID=26990807

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002180843A Expired - Fee Related CA2180843C (fr) 1994-11-10 1995-10-16 Modulateurs a base de pyridine agissant sur les recepteurs de l'acetylcholine

Country Status (9)

Country Link
US (1) US5703100A (fr)
EP (1) EP0739342B1 (fr)
JP (1) JP3802928B2 (fr)
AT (1) ATE248160T1 (fr)
AU (1) AU693285B2 (fr)
CA (1) CA2180843C (fr)
DE (1) DE69531603T2 (fr)
ES (1) ES2204968T3 (fr)
WO (1) WO1996015123A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
JP2002516869A (ja) * 1998-06-05 2002-06-11 レジェンド コート テクノロジーズ モノアミンオキシダーゼ（ｍａｏ）阻害剤とその使用
US6506378B1 (en) 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US7414055B2 (en) 2003-04-24 2008-08-19 Merck & Co., Inc. Inhibitors of Akt activity
CN1809354A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
WO2004103991A1 (fr) * 2003-05-20 2004-12-02 'chemical Diversity Research Institute', Ltd. Piperidines 2-substituees, bibliotheque focalisee et composition pharmaceutique
RU2259364C1 (ru) * 2004-04-01 2005-08-27 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, включающие фрагмент пиперидин-2-ила-, фокусированные библиотеки и фармацевтические композиции
DE60329721D1 (de) * 2003-11-17 2009-11-26 Univ North Carolina State Regiospezifische synthese von nikotinderivaten
JP4639327B2 (ja) * 2004-07-16 2011-02-23 国立大学法人高知大学 光学活性アミノピリジル基含有ピロリジン誘導体及びそれを用いた不斉合成方法
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US7820826B2 (en) * 2006-03-29 2010-10-26 North Carolina State University Synthesis and regioselective substitution of 6-halo-and 6-alkoxy nicotine derivatives
CN103977003A (zh) 2007-04-02 2014-08-13 帕金森氏病研究院 用于降低治疗的副作用的方法和组合物
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
CA3049529A1 (fr) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Dispositifs et methodes d'administration transdermique de medicament
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
CN114437025B (zh) * 2020-11-05 2023-08-25 上海零诺生物科技有限公司 消旋6-甲基烟碱及其制备方法、以及应用
WO2026013602A1 (fr) 2024-07-10 2026-01-15 Rai Strategic Holdings, Inc. Produits à utilisation orale
US20260060287A1 (en) 2024-08-30 2026-03-05 Rai Strategic Holdings, Inc. Aerosolizable composition including a substituted 3-(1-methylpyrrolidin-2-yl)pyridine compound
WO2026083313A2 (fr) 2024-10-18 2026-04-23 Rai Strategic Holdings, Inc. Matériau de type gel de génération d'aérosol comprenant une 3-(1-méthylpyrrolidin-2-yl) pyridine substituée
WO2026083320A1 (fr) 2024-10-18 2026-04-23 Rai Strategic Holdings, Inc. Matériau de production d'aérosol comprenant une 3-(1-méthylpyrrolidine-2-yl)pyridine substituée
WO2026083326A2 (fr) 2024-10-18 2026-04-23 Rai Strategic Holdings, Inc. Matériau de production d'aérosol comprenant un composé 3-(1-méthylpyrrolidine-2-yl)pyridine substitué
WO2026083317A1 (fr) 2024-10-18 2026-04-23 Rai Strategic Holdings, Inc. Matériau de génération d'aérosol en parties distinctes comprenant une 3-(1-méthylpyrrolidin-2-yl)pyridine substituée
WO2026083322A1 (fr) 2024-10-18 2026-04-23 Rai Strategic Holdings, Inc. Bouchon comprenant une 3-(1-méthylpyrrolidine-2-yl)pyridine substituée
WO2026083323A1 (fr) 2024-10-18 2026-04-23 Rai Strategic Holdings, Inc. Additif de modification d'aérosol comprenant une 3-(1-méthylpyrrolidin-2-yl)pyridine substituée

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3247213A (en) * 1961-04-12 1966-04-19 Shell Oil Co Heterocyclic nitrogen compounds
NL7008619A (fr) * 1969-06-25 1970-12-29 Merck & Co Inc
US4155909A (en) * 1977-06-13 1979-05-22 Philip Morris Incorporated 2-Alkyl nicotinoids and processes for their production
US4321387A (en) * 1980-03-21 1982-03-23 Philip Morris, Incorporated Process for the preparation of optically active nicotine analogs
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
EP0412798A3 (en) * 1989-08-08 1992-07-01 Merck Sharp & Dohme Ltd. Substituted pyridines, their preparation, formulations and use in dementia
US5418229A (en) * 1990-01-06 1995-05-23 Alker; David Muscarinic receptor antagonists
DE4038335A1 (de) * 1990-12-01 1992-06-04 Boehringer Mannheim Gmbh Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel
EP0573568B1 (fr) * 1991-03-01 2001-01-24 University Of Florida Research Foundation, Inc. Utilisation des analogues nicotiniques pour le traitement des maladies degeneratives du systeme nerveux
ES2153360T3 (es) * 1991-05-29 2001-03-01 Abbott Lab Compuestos de isoxazol e de isotiazol que mejoran las funciones de razonamiento.
CA2080536A1 (fr) * 1991-10-17 1993-04-18 John S. Ward Activite nicotinique d'une serie d'arecolones et d'isoarecolones
US5242935A (en) * 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5276043A (en) * 1992-04-10 1994-01-04 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5227391A (en) * 1992-04-10 1993-07-13 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5187169A (en) * 1992-04-10 1993-02-16 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5232933A (en) * 1992-05-21 1993-08-03 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5248690A (en) * 1992-07-07 1993-09-28 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
KR100272614B1 (ko) * 1992-08-31 2000-11-15 엠. 잭 오해니언 신경계의 퇴행성 질환의 치료에 유용한 아나바세인 유도체

Also Published As

Publication number Publication date
WO1996015123A1 (fr) 1996-05-23
CA2180843C (fr) 2003-07-15
JP3802928B2 (ja) 2006-08-02
AU693285B2 (en) 1998-06-25
EP0739342B1 (fr) 2003-08-27
EP0739342A1 (fr) 1996-10-30
ATE248160T1 (de) 2003-09-15
US5703100A (en) 1997-12-30
ES2204968T3 (es) 2004-05-01
DE69531603D1 (de) 2003-10-02
JPH09508648A (ja) 1997-09-02
AU3954495A (en) 1996-06-06
DE69531603T2 (de) 2004-06-24

Similar Documents

Publication Publication Date Title
CA2180843A1 (fr) Modulateurs a base de pyridine agissant sur les recepteurs de l'acetylcholine
WO1996031475A3 (fr) Derives de pyridines substituees, leur preparation et leur emploi comme modulateurs de recepteurs d'acetylcholine
ATE240942T1 (de) Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren
PL316143A1 (en) Precursors of morpholinic tachykinin receptor antagonists
CA2359116A1 (fr) Porphyrines substituees
MX9706969A (es) 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
EP1849478A3 (fr) Antagonistes du médiateur inflammatoire
WO2002048124A3 (fr) Derives de piperazine
EP0835869A3 (fr) Agonistes du Récepteur sérotonine 5-HT1F
BG104819A (en) Substituted indolealkanoic acids
CA2316265A1 (fr) Procede et dispositif pour l'imagerie ultrasonique d'un puits tube
IL112847A (en) Isoxazoline compounds as inhibitors of tnf release
AU7261196A (en) N-{2-substituted-3-(2-aminoethyl)-1h-indol-5-yl}-amides: new 5-ht1f agonists
MY122278A (en) 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
WO2000027379A3 (fr) Compositions pharmaceutiques contenant des porphyrines et des derives nouveaux de la porphyrine
ZA983325B (en) NK-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome.
AU5969396A (en) Novel N-(4-oxo-2,3,4,5-tetrahydro-1H-1, 5-benzodiazepin-3yl)-3-amides
ZA983704B (en) Phosphodiesterase 4-inhibiting diazepinoindolones.
CA2168131A1 (fr) Tetrahydro-1h-benzazepinones renfermant des substituts acides
EP0379145A3 (fr) Acides quinoline carboxyliques substitués
WO2001066690A3 (fr) Nouveaux composes
DE69813565D1 (de) Substituierte 3,3-diamino-2-propennitrile, ihre herstellung und verwendung
CA2268327A1 (fr) Derives 3-carboxamide de 5h-pyrrolo[2,1-c][1,4]-benzodiazepines
MXPA02009549A (es) Imidazopiridinas triciclicas.
NO20065489L (no) Tieno[3,2-b]pyridin-6-karbonitriler som protein-kinase inhibitorer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed